Modus Therapeutics Holding AB, a company developing treatments for patients with high unmet medical needs, said that Symbiosis Pharmaceutical Services, a specialist contract manufacturing organization (CMO), has started manufacturing sevuparin drug product securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation. This follows a recent drug supply agreement between Modus and Symbiosis covering the drug product needs for ...